Torrent Pharmaceuticals Limited has announced its financial results for the quarter and half-year ending 30th September 2026. The Board of Directors approved the audited standalone financial results and the unaudited consolidated financial results during their meeting on 23rd October 2026. The meeting, which commenced at 2:00 pm and concluded at 4:00 pm, was conducted in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company has provided an extract of the unaudited consolidated financial results as per Regulation 47 of the SEBI Listing Regulations. These results will be made available on the company’s official website, ensuring transparency and accessibility for stakeholders. Additionally, a press release summarising the financial performance has been prepared for media dissemination.
The independent auditor’s report, conducted by BS R & Co. LLP, expressed a positive opinion on the standalone financial results. The audit covered the financial performance for the quarter ended 30th September 2026, as well as the year-to-date results from 1st April 2026 to 30th September 2026. The report confirmed that the financial statements were prepared in accordance with the applicable accounting standards and provided a true and fair view of the company’s financial position.
The auditor’s report also highlighted that the standalone financial results included the financial information of J. B. Chemicals & Pharmaceuticals Limited, following its amalgamation with Torrent Pharmaceuticals. This merger was approved by the National Company Law Tribunal, with an appointed date of 21st January 2026.
Market analysts will be closely monitoring these results, as they provide insight into Torrent Pharmaceuticals’ financial health and strategic direction post-amalgamation. The company’s ability to maintain transparency and adhere to regulatory requirements is likely to bolster investor confidence in its operations.
